Navigation Links
Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
Date:2/29/2008

ar ended December 31, 2006, to $77.7 million, and represented 10.1% of total revenues. The increase was due primarily to costs associated with the in-license of three Phase III products in support of the Company's branded division, Strativa. In June, the Company paid $3.0 million to Immtech Pharmaceuticals for the US commercialization rights to parfuramidine maleate. In July, the Company paid $15.0 million to BioAlliance Pharma for the US commercialization rights to Loramyc. In August, the Company acquired the North American commercial rights from Hana Biosciences, Inc. ("HANA") for Zensana(TM), at which time the Company made a $5.0 million equity investment in Hana at a contractually agreed premium. Of this amount, $1.2 million representing the premium paid was charged to R&D expense. In support of the Company's generic business, Par made a $5.0 million equity investment in IntelliPharmaCeutics Ltd., a privately held corporation, to develop and market four controlled release generic drug products. Of this amount, approximately $2.5 million, representing the premium paid, was charged to R&D.

Selling, general and administrative (SG&A) expense for the year ended December 31, 2007 decreased 6.9% to $138.2 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of the second quarter 2006 write-off of approximately $10 million in bad debt for invalid customer deductions that the Company determined would not be pursued for collection, lower net severance costs, partially offset by the expansion of finance and accounting functions, higher other compensation related costs, including costs associated with the fourth quarter 2007 tender offer to repurchase certain unvested stock options, and increased professional costs related to the Company's restatement of prior periods.

Fourth Quarter 2007 Review

Total revenues of $155.1 million for the fourth quarter ended December 31, 2007, decreased 15.5% compared with the same period in
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
2. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
5. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
8. Lotus Pharmaceuticals Raises $5 Million in Private Placement
9. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 Ryadon ... a wide range of capabilities and services to complement ... , Ryadon's Quantity Discount Program will be offered on ... follows: , Order 4-19: Receive 10% discount - Order ... by Using the Drawer Slides Products, ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had the ... contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, sponsored ... of which Wickstrom is the founder. Making appearances at ... EcoLuxe Lounge is a gathering of some of the ... and services. Among the many roles that she has ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements focused ... A unique combination of herbs and nutrients, including ... apart from other antioxidant supplements. This formula relies ... versus the use of single or sequential compounds ... Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® Glutathione. ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s provider ... cannabis, is taking a leadership role in ensuring Canadian ... NAC is the first to back mdBriefCase Group Inc.'s ... will be providing 300 healthcare professionals with free access ... Canadians gain safe and responsible access to medical cannabis ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... SOMERSET, N.J., Nov. 9 inVentiv Health Inc.,(Nasdaq: ... a new Client Development,and Integration team. The team will ... Chief Client Development Officer. The Client Development and ... segments to identify new opportunities to,serve both new and ...
... Interferon does not slow or halt the progression of ... who havent responded to previous attempts to eradicate the ... University School of Medicine participated has found. , Patients ... experience a significant decrease in viral levels and liver ...
... and techniques of soft condensed matter physics, a research team ... of attractions between proteins keeps the lens of the eye ... can cause proteins to aggregate and de-mix. This leads to ... could shed light on other protein aggregation diseases (such as ...
... after stopping the drug, researchers say , , FRIDAY, Nov. ... at a slightly increased risk for developing cervical cancer, ... very small risk disappears, a new British study suggests. ... women to continue getting screened for cervical cancer, experts ...
... 24 and Taclonex; Company ... financial guidance, ST. DAVID,S, Bermuda, Nov. 9 Warner Chilcott,Limited ... ended,September 30, 2007. Revenue in the quarter ended September 30, 2007 ... The,primary drivers of the increase in revenue were the net sales ...
... Global Commercialization, Program for Once-Daily Tramadol and Completion of Enrolment ... ... QC, Nov. 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) ... ended September 30, 2007. All figures are in Canadian dollars ...
Cached Medicine News:Health News:inVentiv Health Creates Client Development and Integration Team 2Health News:inVentiv Health Creates Client Development and Integration Team 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Physics provides new insights on cataract formation 2Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
(Date:4/23/2015)... Once again, BeaconMedaes is meeting healthcare facilities, ... safety. BeaconMedaes, priority is to partner with ... The next generation Zone Valve Box assembly strengthens ... mounted in the assembly, allowing for ease of sensor ... potentially releasing dust spores and other bacteria within the ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... NEW YORK, April 7, 2011 Reportlinker.com announces ... in its catalogue: European ... http://www.reportlinker.com/p0470760/European-Markets-for-Interventional-Cardiology-Devices-2011-15-Countries.html ... cardiology devices were valued at over euro1.5 billion. ...
... Reportlinker.com announces that a new market research report ... Global: Pharmaceuticals Industry Guide ... Guide is an essential resource for top-level data ... includes detailed data on market size and segmentation, ...
Cached Medicine Technology:Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 2Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 3Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 4Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 5Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 6Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 7Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 8Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 9Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 10Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 11Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 12Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 13Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 14Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 15Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 16Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 17Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 18Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 19Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 20Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 21Reportlinker Adds Global: Pharmaceuticals Industry Guide 2Reportlinker Adds Global: Pharmaceuticals Industry Guide 3Reportlinker Adds Global: Pharmaceuticals Industry Guide 4Reportlinker Adds Global: Pharmaceuticals Industry Guide 5Reportlinker Adds Global: Pharmaceuticals Industry Guide 6Reportlinker Adds Global: Pharmaceuticals Industry Guide 7Reportlinker Adds Global: Pharmaceuticals Industry Guide 8
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: